Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer

A. Cometta, T. Calandra, H. Gaya, S. H. Zinner, R. De Bock, A. Del Favero, G. Bucaneve, F. Crokaert, W. V. Kern, J. Klastersky, J. Langenaeken, A. Micozzi, A. Padmos, M. Paesmans, C. Viscoli, M. P. Glauser, P. Martino, D. Caballero, W. V. Kern, D. EngelhardM. Shapiro, E. Castagnola, L. Massimo, R. Giacchino, M. Sanz, M. Giacchino, M. Aoun, B. Oppenheim, D. D'Antonio, F. Follath, G. Barbabietola, F. Menichetti, M. Montillo, M. T. Van Lint, A. Cometta, B. Gibson, L. Resegotti, C. Kibbler, H. Prentice, A. Van Hoof, H. Van Landuyt, P. Ricci, G. Rosti, A. Efremidis, F. Di Raimondo, R. Hemmer, M. Hatjiyanni, B. Seitanides, D. Amsallen, J. M. Estavoyer, G. Petrikkos, A. Porcellini, Z. Berneman

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences